| Overall (N=96） | greater response group （N=23） | none-greater response group （N=73） | P value | |
|---|---|---|---|---|
| Age (year) | 56.7±9.5 | 59.2±10.7 | 55.9±9.0 | 0.1512 |
| Male (%) | 58 (60.4%) | 13 (56.5%) | 45 (61.6%) | 0.8073 |
| Height (cm) | 164.9±8.9 | 163.8±7.7 | 165.2±9.2 | 0.5064 |
| Weight (kg) | 82.7 (75.9-97.6) | 81.2 (71.9-89.6) | 83.5 (77.6-98.1) | 0.3846 |
| BMI (kg/m2) | 30.8 (28.7-34.5) | 30.1 (28.1-31.9) | 31.7 (28.9-34.7) | 0.4783 |
| Hemoglobin A1c (%) | 7.0 (6.3-7.8) | 6.6 (6.0-7.2) | 7.1 (6.4-8.3) | 0.0666 |
| Aspartate aminotransferase (IU/L) | 25 (19-35) | 25 (20-36) | 26 (19-35) | 0.6619 |
| Alanine aminotransferase (IU/L) | 28 (20-42) | 27 (17-37) | 28 (23-43) | 0.1955 |
| γ-glutamyl transpeptidase (IU/L) | 28 (20-49) | 26 (23-51) | 30 (20-48) | 0.3606 |
| Total cholesterol (mg/dL) | 150 (132-182) | 144 (132-188) | 150 (131-181) | 0.3936 |
| HDL-cholesterol (mg/dL) | 45 (38-51) | 47 (43-58) | 44 (37-51) | 0.0058 |
| LDL-cholesterol (mg/dL) | 75 (59-91) | 72 (58-97) | 75 (59-87) | 0.4271 |
| Triglycerides (mg/dL) | 141 (98-216) | 130 (98-176) | 141 (98-220) | 0.2486 |
| eGFR (ml/min/1.73 m2) | 73.0 (61.0-83.3) | 76.2 (53.2-83.8) | 72.4 (61.4-83.3) | 0.8153 |
| Antidiabetic medicines (%) | ||||
| Insulin (combined) | 37 (47.4%) | 8 (34.8%) | 29 (39.7%) | 0.8072 |
| Sulfonylureas (combined) | 24 (24.7%) | 4 (17.4%) | 20 (27.3%) | 0.4161 |
| Glinides (combined) | 4 (4.1%) | 2 (8.7%) | 2 (2.7%) | 0.2417 |
| DPP-4 inhibitor (switched) | 7 (7.2%) | 2 (8.7%) | 5 (6.8%) | 0.6715 |
| GLP-1 receptor agonists (switched) | 70 (72.2%) | 12 (52.2%) | 58 (79.5%) | 0.0154 |
| SGLT-2 inhibitor (combined) | 81 (83.5%) | 20 (87.0%) | 61 (83.6%) | 1.0000 |
| Metformin (combined) | 56 (57.7%) | 15 (65.2%) | 41 (56.2%) | 0.4779 |
| Thiazolidinedione (combined) | 8 (8.2%) | 1 (4.3%) | 7 (9.6%) | 0.6752 |
| Alpha-glucosidase inhibitor (combined) | 5 (5.2%) | 3 (13.0%) | 2 (2.7%) | 0.0873 |
| Simple regression | Multivariate regression | |||||
|---|---|---|---|---|---|---|
| OR | 95%CI for Odds ratio | P-value | OR | 95%CI for Odds ratio | P-value | |
| Age (per 1.0year) | 1.0381 | 0.9862 - 1.0928 | 0.1527 | |||
| Sex (male) | 1.2363 | 0.4782 - 3.1961 | 0.6616 | 1.1255 | 0.4016 - 3.1544 | 0.8221 |
| Height (per 1.0 cm) | 0.9818 | 0.9304 - 1.0360 | 0.5022 | |||
| Weight (per 1.0 kg) | 0.9870 | 0.9584 - 1.0164 | 0.3816 | |||
| BMI (per 1.0 kg/m2) | 0.9613 | 0.8629 - 1.0710 | 0.4744 | |||
| Hemoglobin A1c (per 1.0 %) | 0.7091 | 0.4861 - 1.0344 | 0.0744 | |||
| Aspartate aminotransferase (per 1.0 IU/L) | 0.9935 | 0.9651 - 1.0227 | 0.6589 | |||
| Alanine aminotransferase (per 1.0 IU/L) | 0.9811 | 0.9530 - 1.0101 | 0.1994 | |||
| γ-glutamyl transpeptidase (per 1.0 IU/L) | 1.0064 | 0.9926 - 1.0203 | 0.3656 | |||
| Total cholesterol (per 1.0 mg/dL) | 1.0054 | 0.9931 - 1.0178 | 0.3907 | |||
| HDL-cholesterol (per 1.0 mg/dL) | 1.0522 | 1.0103 - 1.0959 | 0.0140 | 1.0472 | 1.0059 - 1.0902 | 0.0248 |
| LDL-cholesterol (per 1.0 mg/dL) | 1.0067 | 0.9904 - 1.0232 | 0.4240 | |||
| Triglycerides (per 1.0 mg/dL) | 0.9963 | 0.9902 - 1.0023 | 0.2270 | |||
| eGFR (per 1.0 ml/min/1.73 m2) | 0.9977 | 0.9790 - 1.0168 | 0.8130 | |||
| Insulin (versus no use) | 0.8092 | 0.3044 - 2.1513 | 0.6713 | |||
| Sulfonylureas (versus no use) | 0.5579 | 0.1689 - 1.8423 | 0.3383 | |||
| Glinides (versus no use) | 3.3810 | 0.4487 - 25.4747 | 0.2371 | |||
| DPP-4 inhibitor (versus no use) | 1.2952 | 0.2340 - 7.1704 | 0.7670 | |||
| GLP-1 RA (versus no use) | 0.2821 | 0.1042 - 0.7637 | 0.0128 | 0.3105 | 0.1106 - 0.8718 | 0.0264 |
| SGLT-2 inhibitor (versus no use) | 1.3115 | 0.3359 - 5.1211 | 0.6964 | |||
| Metformin (versus no use) | 1.4634 | 0.5522 - 3.8786 | 0.4439 | |||
| Thiazolidinedione (versus no use) | 0.4286 | 0.0499 - 3.6797 | 0.4399 | |||
| Alpha-glucosidase inhibitor (versus no use) | 5.3250 | 0.8317 - 34.0942 | 0.0775 | |||
